Cochrane · systematic review · CD011205
Guanylate cyclase stimulators for pulmonary hypertension
Wardle, AJ, Seager, MJ, Wardle, R, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table
Population: Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in Exercise Capacity (6MWD) | no estimate extracted | 2 studies · 398 participants | Very low Downgraded: indirectness |
Mortality | OR 0.29 [0.05, 1.91] | 2 studies · 398 participants | Low Downgraded: indirectness |
Improvement in WHO Functional Class | OR 1.53 [0.87, 2.71] | 2 studies · 397 participants | Low Downgraded: indirectness |
Serious Adverse Events (Participants with one or more event) | OR 0.93 [0.22, 3.83] | 2 studies · 398 participants | Very low Downgraded: indirectness |